Avenue Therapeutics, Inc. (ATXI): Price and Financial Metrics
ATXI Price/Volume Stats
|Current price||$0.17||52-week high||$2.35|
|Prev. close||$0.17||52-week low||$0.16|
|Day high||$0.17||Avg. volume||837,560|
|50-day MA||$0.38||Dividend yield||N/A|
|200-day MA||$0.87||Market Cap||2.25M|
ATXI Stock Price Chart Interactive Chart >
Avenue Therapeutics, Inc. (ATXI) Company Bio
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes an intravenous formulation of tramadol HCI principally for use in the acute/intensive care hospital setting. Its product candidate is IV Tramadol for the treatment of post-operative pain. The company was founded in 2015 and is based in New York, New York.
ATXI Latest News Stream
|Loading, please wait...|
ATXI Latest Social Stream
View Full ATXI Social Stream
Latest ATXI News From Around the Web
Below are the latest news stories about AVENUE THERAPEUTICS INC that investors may wish to consider to help them evaluate ATXI as an investment opportunity.
- Phase 1b/2a clinical trial of AJ201 remains on track to report topline data in second quarter of 2024 - - Positive BAER-101 preclinical data accepted for presentation at American Epilepsy Society (AES) Annual Meeting - - Agreement reached with U.S. FDA on study design and analysis approach for Phase 3 safety study of IV tramadol - - Raised $5 million in gross proceeds from public equity offering - MIAMI, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or th
Insiders who bought US$251.0k worth of Avenue Therapeutics, Inc.'s ( NASDAQ:ATXI ) stock at an average buy price of...
Pre-market stock movers are a hot topic on Thursday and we're checking out all of the biggest ones worth watching this morning!
MIAMI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the closing of its previously announced public offering of an aggregate of 16,633,400 units (or pre-funded units in lieu thereof) at a public offering price of $0.3006 per unit (inclusive of the pre-funded warrant exercise price of $0
MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the pricing of its public offering of an aggregate of 16,633,400 units at a public offering price of $0.3006 per unit. Each unit consists of (i) one share of common stock (or one pre-funded warrant in lieu thereof), (ii) one Series A
ATXI Price Returns